Real-life Management of Patients Eligible for CAR-T Cell Therapy

Launched by UNIVERSITY HOSPITAL, TOULOUSE · Apr 12, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how patients with blood disorders, specifically those eligible for CAR-T cell therapy, are managed in real-life settings. CAR-T cell therapy is an advanced treatment that uses modified immune cells to fight certain types of blood cancers. While this therapy has shown promise in clinical trials, there is a need to gather more information on how it works for patients in everyday situations. The trial will collect data from patients treated at Toulouse University Hospital to evaluate not just the treatment's effectiveness, but also how it affects patients' quality of life and the barriers they may face in receiving care.

To be eligible for the trial, patients must be receiving CAR-T cell treatment for their blood condition at Toulouse University Hospital from January 1, 2019, to December 31, 2028, and must be able to understand the study and agree to participate. Participants can expect their experiences and outcomes to be tracked, which will help improve care for future patients. It’s important to note that the study aims to explore not only the medical aspects of treatment but also the social factors that may impact a patient's access to care, such as where they live and their overall support systems.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient eligible for CAR-T treatment for hemopathy at TOULOUSE University Hospital under early access or marketing authorization or as part of a clinical trial between 01/01/2019 and 31/12/2028
• • Patient able to understand the purpose and constraints of the research project
• • Patient has read the study information leaflet and does not object to the research.
• Exclusion Criteria:
• • Patient under guardianship, curatorship or safeguard of justice
• • Patient objects to the collection of data concerning him/her